|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 128.97 CHF | +0.46% |
|
+4.61% | +17.50% |
| 06:51am | Novartis Says Chronic Skin Condition Drug Shows Positive Results in Trial | DJ |
| 06:47am | Novartis Reports Positive Results from Phase 3 Trial of Chronic Inducible Urticaria Oral Drug | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 24.02B | 6.96B | 14.85B | 11.94B | 13.98B | |||||
Depreciation & Amortization - CF | 1.53B | 1.47B | 1.18B | 1.14B | 1.23B | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 3.9B | 3.98B | 3.96B | 3.46B | 3.52B | |||||
Depreciation & Amortization, Total | 5.43B | 5.45B | 5.14B | 4.6B | 4.74B | |||||
(Gain) Loss From Sale Of Asset | -677M | -333M | -180M | -74M | 116M | |||||
(Gain) Loss on Sale of Investments - (CF) | -38M | 260M | 106M | 45M | -50M | |||||
Asset Writedown & Restructuring Costs | 684M | 1.73B | 3.14B | 1.47B | 581M | |||||
(Income) Loss On Equity Investments - (CF) | -15.34B | 9M | 15M | 38M | 12M | |||||
Stock-Based Compensation (CF) | 736M | 823M | 865M | 1.04B | 1.1B | |||||
Net Cash From Discontinued Operations | - | - | 238M | - | - | |||||
Other Operating Activities, Total | 1.13B | 1.23B | -7.81B | 369M | 1.72B | |||||
Change In Accounts Receivable | -389M | -589M | -1.5B | -931M | -1.12B | |||||
Change In Inventories | 81M | -830M | -546M | -225M | 34M | |||||
Change In Accounts Payable | -21M | -48M | 479M | -105M | -273M | |||||
Change in Other Net Operating Assets | -549M | -421M | -332M | -552M | -1.7B | |||||
Cash from Operations | 15.07B | 14.24B | 14.46B | 17.62B | 19.14B | |||||
Capital Expenditure | -1.38B | -1.2B | -1.06B | -1.37B | -1.55B | |||||
Sale of Property, Plant, and Equipment | 240M | 167M | 237M | 86M | 13M | |||||
Cash Acquisitions | -633M | -864M | -3.56B | -4.02B | -2.92B | |||||
Divestitures | 66M | -15M | 3M | 107M | -88M | |||||
Sale (Purchase) of Intangible assets | -845M | -1.27B | 262M | -2.37B | -2.19B | |||||
Investment in Marketable and Equity Securities, Total | 6.82B | 4.65B | 10.84B | 43M | 1.87B | |||||
Other Investing Activities, Total | -57M | -1M | -1.12B | 3M | -24M | |||||
Cash from Investing | 4.21B | 1.47B | 5.6B | -7.51B | -4.88B | |||||
Short Term Debt Issued, Total | - | 295M | 546M | 958M | 5M | |||||
Long-Term Debt Issued, Total | 16M | 16M | - | 6.14B | 6.1B | |||||
Total Debt Issued | 16M | 311M | 546M | 7.1B | 6.1B | |||||
Short Term Debt Repaid, Total | -3.52B | - | - | -289M | - | |||||
Long-Term Debt Repaid, Total | -2.48B | -2.87B | -2.48B | -2.42B | -3.67B | |||||
Total Debt Repaid | -6B | -2.87B | -2.48B | -2.71B | -3.67B | |||||
Issuance of Common Stock | 53M | 100M | 153M | 30M | 27M | |||||
Repurchase of Common Stock | -3.06B | -10.65B | -8.72B | -8.33B | -9.21B | |||||
Common Dividends Paid | -7.37B | -7.51B | -7.26B | -7.62B | -7.82B | |||||
Common & Preferred Stock Dividends Paid | -7.37B | -7.51B | -7.26B | -7.62B | -7.82B | |||||
Other Financing Activities, Total | 94M | 55M | 3.48B | -207M | -294M | |||||
Cash from Financing | -16.26B | -20.56B | -14.28B | -11.74B | -14.87B | |||||
Foreign Exchange Rate Adjustments | -266M | -32M | 100M | -298M | 576M | |||||
Net Change in Cash | 2.75B | -4.89B | 5.88B | -1.93B | -24M | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 664M | 696M | 751M | 855M | 981M | |||||
Cash Income Tax Paid (Refund) | 2.34B | 1.98B | 2.79B | 2.26B | 2.56B | |||||
Levered Free Cash Flow | 13.12B | 9.69B | 12.13B | 12.04B | 12.12B | |||||
Unlevered Free Cash Flow | 13.62B | 10.21B | 12.67B | 12.67B | 12.83B | |||||
Change In Net Working Capital | -1.42B | 1.85B | 713M | -295M | 1.39B | |||||
Net Debt Issued / Repaid | -5.99B | -2.56B | -1.94B | 4.39B | 2.43B |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















